Overview
Ireland-based biopharma's Q4 revenue rose 10% yr/yr, beating analyst expectations
Adjusted EPS for Q4 beat analyst expectations
Company expects 2026 revenue of $4.25 to $4.50 bln
Outlook
Jazz Pharmaceuticals expects 2026 total revenue of $4.25 to $4.50 bln
Company anticipates double-digit growth in epilepsy and oncology franchises in 2026
Jazz plans sBLA submission for zanidatamab in 1Q26, potential launch in 2H26
Result Drivers
XYWAV SALES - Xywav net product sales increased 12% to $1.7 bln in 2025, driven by strong new patient growth
MODEYSO LAUNCH - Modeyso generated $37 mln in revenue in its first full quarter on the market
Company press release: ID:nPn56DHWZa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $1.20 bln | $1.17 bln (13 Analysts) |
Q4 Adjusted EPS | Beat | $6.64 | $6.52 (14 Analysts) |
Q4 EPS | $3.21 | ||
Q4 Adjusted Net Income | Beat | $420.89 mln | $405.88 mln (13 Analysts) |
Q4 Net Income | $203.45 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $219.50, about 26.7% above its February 23 closing price of $173.25
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 7 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)